RU2003113536A - Кристаллические формы гидрохлорида 1-[6-хлор-5-(трифторметил)-2-пиридинил]пиперазина - Google Patents
Кристаллические формы гидрохлорида 1-[6-хлор-5-(трифторметил)-2-пиридинил]пиперазинаInfo
- Publication number
- RU2003113536A RU2003113536A RU2003113536/04A RU2003113536A RU2003113536A RU 2003113536 A RU2003113536 A RU 2003113536A RU 2003113536/04 A RU2003113536/04 A RU 2003113536/04A RU 2003113536 A RU2003113536 A RU 2003113536A RU 2003113536 A RU2003113536 A RU 2003113536A
- Authority
- RU
- Russia
- Prior art keywords
- pyridinyl
- trifluoromethyl
- chloro
- peaks
- piperazine
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims 3
- FVDILXYXZAAJOS-UHFFFAOYSA-N 1-[6-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazine;hydrochloride Chemical compound Cl.N1=C(Cl)C(C(F)(F)F)=CC=C1N1CCNCC1 FVDILXYXZAAJOS-UHFFFAOYSA-N 0.000 title claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- QZYYPQAYSFBKPW-UHFFFAOYSA-N org 12962 Chemical compound N1=C(Cl)C(C(F)(F)F)=CC=C1N1CCNCC1 QZYYPQAYSFBKPW-UHFFFAOYSA-N 0.000 claims 6
- 238000001228 spectrum Methods 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- 238000010992 reflux Methods 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000009835 boiling Methods 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- -1 compound 1- [6-chloro-5- (trifluoromethyl) -2-pyridinyl] piperazine hydrochloride Chemical class 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3403—Needle locating or guiding means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4887—Locating particular structures in or on the body
- A61B5/489—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3403—Needle locating or guiding means
- A61B2017/3405—Needle locating or guiding means using mechanical guide means
- A61B2017/3409—Needle locating or guiding means using mechanical guide means including needle or instrument drives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3403—Needle locating or guiding means
- A61B2017/3413—Needle locating or guiding means guided by ultrasound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/44—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for cooling or heating the devices or media
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Claims (9)
1. Соединение гидрохлорид 1-[6-хлор-5-(трифторметил)-2-пиридинил]пиперазина (Org 12962) в чистой кристаллической форме, которая совершенно или фактически не содержит других кристаллических форм.
2. Соединение по п.1, имеющее кристаллическую форму А, которая характеризуется порошковым рентгенодифракционным спектром, полученным с помощью CuKα1 излучения, с пиками при значениях 2-тета (2θ): 17,50°; 17,80°; 23,85°; 24,50°; 25,55°; 27,75° и 29,40° и спектром координационного рассеяния с пиками при 82,2 см-1; 106,6 см-1; 194,7 см-1; 211,2 см-1; 356,5 см-1; 1037,6 см-1; 1268,2 см-1; 2997,0 см-1; 3006,5 см-1 и 3122,4 см-1.
3. Соединение по п.1, имеющее кристаллическую форму В, которая характеризуется порошковым рентгенодифракционным спектром, полученным с помощью CuKα1 излучения, с пиками при значениях 2-тета (2θ): 20,40°; 21,05°; 24,80°; 25,80° и 28,10° и спектром координационного рассеяния с пиками при 104,6 см-1; 147,7 см-1; 192,8 см-1; 209,5 см-1; 360,6 см-1; 1035,9 см-1; 1265,3 см-1; 2997,1 см-1; 3001,8 см-1 и 3117,2 см-1.
4. Способ получения соединения, определенного в п.2, характеризующийся тем, что концентрированный раствор гидрохлоридной соли 1-[6-хлор-5-(трифторметил)-2-пиридинил]пиперазина в смеси этанол/вода быстро охлаждают до температуры ниже 0°С, после чего начинается спонтанное образование зародышей кристаллов.
5. Способ получения соединения по п.3, отличающийся тем, что концентрированный раствор 1-[6-хлор-5-(трифторметил)-2-пиридинил]пиперазина в смеси этанол/вода обрабатывают избытком соляной кислоты при температуре кипения с обратным холодильником, что вызывает образование зародышей кристаллов при температуре кипения с обратным холодильником, после чего раствор медленно охлаждают до комнатной температуры.
6. Способ получения соединения по п.3, отличающийся тем, что суспензию полиморфного гидрохлорида 1-[6-хлор-5-(трифторметил)-2-пиридинил]пиперазина в смеси этанол/вода сохраняют до полного превращения в форму В.
7. Способ по п.6, в котором суспензию хранят при температуре кипения с обратным холодильником.
8. Фармацевтическая композиция, включающая фармацевтически приемлемый наполнитель и Org 12962, отличающаяся тем, что Org 12962 находится, главным образом, в чистой кристаллической форме В, характеризующейся порошковым рентгенодифракционным спектром, полученным с помощью CuKα1 излучения, с пиками при значениях 2-тета (2θ): 20,40°; 21,05°; 24,80°; 25,80° и 28,10° и спектром координационного рассеяния с пиками при 104,6 см-1; 147,7 см-1; 192,8 см-1; 209,5 см-1; 360,6 см-1; 1035,9 см-1; 1265,3 см-1; 2997,1 см-1; 3001,8 см-1 и 3117,2 см-1.
9. Способ лечения депрессии, беспокойства, ожирения и недержания мочи у млекопитающих, включающий введение терапевтически эффективного количества гидрохлорида 1-[6-хлор-5-(трифторметил)-2-пиридинил]пиперазина в чистой кристаллической форме по п.3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00203528.5 | 2000-10-13 | ||
| EP00203528 | 2000-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2003113536A true RU2003113536A (ru) | 2004-11-10 |
Family
ID=8172124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003113536/04A RU2003113536A (ru) | 2000-10-13 | 2001-10-09 | Кристаллические формы гидрохлорида 1-[6-хлор-5-(трифторметил)-2-пиридинил]пиперазина |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20040038985A1 (ru) |
| EP (1) | EP1326837A1 (ru) |
| JP (1) | JP2004512282A (ru) |
| KR (1) | KR20030060906A (ru) |
| CN (1) | CN1469863A (ru) |
| AU (1) | AU2002220614A1 (ru) |
| BR (1) | BR0114609A (ru) |
| CA (1) | CA2425540A1 (ru) |
| EC (1) | ECSP034549A (ru) |
| HR (1) | HRP20030246A2 (ru) |
| HU (1) | HUP0302842A2 (ru) |
| IL (1) | IL154982A0 (ru) |
| IS (1) | IS6758A (ru) |
| MX (1) | MXPA03003233A (ru) |
| NO (1) | NO20031698D0 (ru) |
| PL (1) | PL366055A1 (ru) |
| RU (1) | RU2003113536A (ru) |
| SK (1) | SK4332003A3 (ru) |
| WO (1) | WO2002030902A1 (ru) |
| ZA (1) | ZA200302520B (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008004944A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | Novel crystalline form ii |
| WO2008004945A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | Novel crystalline forms i and ii |
| CZ2011810A3 (cs) * | 2011-12-12 | 2013-07-10 | Masarykova Univerzita | Zpusob prípravy 1-(pyridin-4-yl)piperazinu a jeho 1,1-dialkyl-1-ium derivátu |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2061953T3 (es) * | 1988-11-24 | 1994-12-16 | Akzo Nv | Un procedimiento para preparar una composicion farmaceutica. |
| WO1998033504A1 (en) * | 1997-02-03 | 1998-08-06 | Akzo Nobel N.V. | Treatment of urinary incontinence |
-
2001
- 2001-10-09 CN CNA018172571A patent/CN1469863A/zh active Pending
- 2001-10-09 AU AU2002220614A patent/AU2002220614A1/en not_active Abandoned
- 2001-10-09 SK SK433-2003A patent/SK4332003A3/sk unknown
- 2001-10-09 EP EP01986679A patent/EP1326837A1/en not_active Withdrawn
- 2001-10-09 RU RU2003113536/04A patent/RU2003113536A/ru not_active Application Discontinuation
- 2001-10-09 MX MXPA03003233A patent/MXPA03003233A/es unknown
- 2001-10-09 KR KR10-2003-7005122A patent/KR20030060906A/ko not_active Application Discontinuation
- 2001-10-09 US US10/398,991 patent/US20040038985A1/en not_active Abandoned
- 2001-10-09 HU HU0302842A patent/HUP0302842A2/hu unknown
- 2001-10-09 JP JP2002534288A patent/JP2004512282A/ja not_active Withdrawn
- 2001-10-09 PL PL01366055A patent/PL366055A1/xx not_active Application Discontinuation
- 2001-10-09 WO PCT/EP2001/011714 patent/WO2002030902A1/en not_active Application Discontinuation
- 2001-10-09 CA CA002425540A patent/CA2425540A1/en not_active Abandoned
- 2001-10-09 BR BR0114609-2A patent/BR0114609A/pt not_active Application Discontinuation
- 2001-10-09 IL IL15498201A patent/IL154982A0/xx unknown
-
2003
- 2003-03-27 IS IS6758A patent/IS6758A/is unknown
- 2003-03-31 ZA ZA200302520A patent/ZA200302520B/en unknown
- 2003-04-01 HR HR20030246A patent/HRP20030246A2/hr not_active Application Discontinuation
- 2003-04-08 EC EC2003004549A patent/ECSP034549A/es unknown
- 2003-04-11 NO NO20031698A patent/NO20031698D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP034549A (es) | 2003-05-26 |
| CA2425540A1 (en) | 2002-04-18 |
| IL154982A0 (en) | 2003-10-31 |
| NO20031698D0 (no) | 2003-04-11 |
| PL366055A1 (en) | 2005-01-24 |
| US20040038985A1 (en) | 2004-02-26 |
| EP1326837A1 (en) | 2003-07-16 |
| WO2002030902A8 (en) | 2004-02-26 |
| HUP0302842A2 (hu) | 2003-12-29 |
| MXPA03003233A (es) | 2003-09-10 |
| SK4332003A3 (en) | 2003-10-07 |
| ZA200302520B (en) | 2004-06-30 |
| IS6758A (is) | 2003-03-27 |
| CN1469863A (zh) | 2004-01-21 |
| BR0114609A (pt) | 2003-12-23 |
| WO2002030902A1 (en) | 2002-04-18 |
| KR20030060906A (ko) | 2003-07-16 |
| HRP20030246A2 (en) | 2003-06-30 |
| AU2002220614A1 (en) | 2002-04-22 |
| JP2004512282A (ja) | 2004-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6724082B2 (ja) | 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５−ＨＴ３および５−ＨＴ１Ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）−フェニル］ピペラジン | |
| RU2382039C2 (ru) | Способ получения 2-аминотиазол-5-ароматических карбоксамидов в качестве ингибиторов киназ | |
| JP5301501B2 (ja) | ヒスタミンｈ３−受容体リガンドとしての非イミダゾールアルキルアミンと、その治療への応用 | |
| JP5371790B2 (ja) | 睡眠および認知に関するうつ病における残存症状の治療のための組み合わされたセロトニン再取り込み、５−ｈｔ３および５−ｈｔ１ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）フェニル］ピペラジン | |
| JP4137159B2 (ja) | セロトニン及びノルアドレナリン再取り込み阻害薬としてのｎ−ピロリジン−３−イル−アミド誘導体 | |
| RU2007141198A (ru) | Кристаллическая форма малеата азенапина | |
| SK391091A3 (en) | Crystalline paroxetine hydrochloride hemihydrate, pharmacuetical composition containing the same and its use | |
| SK288334B6 (sk) | Polymorfná kryštalická forma V 1-[4-(5-kyanoindol-3-yl)butyl]-4- (2-karbamoylbenzofuran-5-yl) piperazín hydrochlorid monohydrátu, spôsoby jej prípravy, použitie a farmaceutická kompozícia s jej obsahom | |
| SK6252000A3 (en) | Indazole bioisostere replacement of catechol in therapeutically active compounds | |
| EA007537B1 (ru) | Азотсодержащие гетероциклические производные, содержащая их фармацевтическая композиция, их применение и способ лечения | |
| CZ285409B6 (cs) | Polycyklické aminosloučeniny a jejich enantiomery, způsob jejich přípravy a farmaceutické prostředky, které je obsahují | |
| JP2009137943A (ja) | アゴメラチンの新規な結晶形ｖｉ、その製造法、およびそれを含有する薬学的組成物 | |
| JP2012519715A (ja) | アゴメラチンの新規結晶形態ｖｉ、製造方法及びその応用 | |
| WO2005021536A2 (en) | Adamantane and azabicyclo-octane and nonane derivatives, process of their preparation and their use as dpp-iv inhibitors | |
| RU2007148072A (ru) | Кристаллические формы 4-[(2,4-дихлор-5-метоксифинил)амино]-6- меокси-7-[3-(4-метил-1-пиперазинил)пропокси]-3-хиналинкарбонитрил и способы их получения | |
| AU2009309674A1 (en) | Novel salts of sunitinib | |
| DE602004004378T2 (de) | Verbindungen mit einer 5-ht2c rezeptor-wirkung und ihre verwendung | |
| MX2012009480A (es) | Nueva forma cristalina de un derivado de ciclopropilbenzamida. | |
| JP2017535566A (ja) | 疼痛に対する多様な活性を有する１，９−ジアザスピロウンデカン化合物 | |
| RU2003113536A (ru) | Кристаллические формы гидрохлорида 1-[6-хлор-5-(трифторметил)-2-пиридинил]пиперазина | |
| EP2617723A2 (en) | Novel compound acting as a cannabinoid receptor-1 inhibitor | |
| JP5600253B2 (ja) | 情動障害の治療のための［２−（６−フルオロ−１ｈ−インドール−３−イルスルファニル）ベンジル］メチルアミン | |
| CN112351977A (zh) | 治疗异常增殖性疾病的药剂和方法 | |
| US4567181A (en) | Bicyclo (4.2.0) 1,3,5-octatriene compounds and use as α-adrenergics | |
| EP2905278A1 (en) | Heteroaromatic compounds, method for preparing the compounds, pharmaceutical compositions, uses and method for treating acute and chronic pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20050111 |